96 Tests PN: B111127

Components:

45x Ab-conjugated beads (S5P10 - human IFN-alpha/IFNA (pan) -bead). PN: B111127A. One vial containing 100 µL of anti-human IFN-alpha/IFNA (pan) conjugated to AimPlex Bead S5P10.

25x Biotin-detection Ab (human IFN-alpha/IFNA (pan) Biotin-dAb). PN: B111127B. One vial containing 100 µL of biotinylated anti-human IFN-alpha/IFNA (pan).

Lyophilized Standard - Human IFN-alpha/IFNA (pan). PN: B111127S. One vial containing lyophilized IFN-alpha/IFNA (pan).

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Application: Optimal antibody pair and antigen standard for assaying human IFN-alpha/IFNA (pan). To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

IFNalpha is one of the type I interferons (IFN)s and it is mainly involved in innate immunity. IFNalpha is primarily produced by macrophages resulting from viral infections and activates anti-viral and immunomodulatory activities in target cells. An abnormal production of IFN-alpha induces immune dysfunction such as autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis...) or mediates tissue inflammation.

References:

  1. Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 2015; 26(2): 121-31. Doi: 10.1016/j.cytogfr.2014.12.006.

  2. Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354(7): 709-18. Doi: 10.1056/NEJMoa053007.